NASDAQ:NBRV
Delisted
Nabriva Therapeutics AG Stock News
$1.42
+0 (+0%)
At Close: Nov 24, 2023
5 Best Stocks With Rising P/E to Buy for Solid Returns
07:35am, Monday, 05'th Apr 2021
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd Apr 2021
DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a
Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
08:00am, Thursday, 01'st Apr 2021
DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in
NBRV Stock Price Increases Over 15% Pre-Market: Why It Happened
06:50am, Wednesday, 17'th Mar 2021
The stock price of Nabriva Therapeutics PLC (NASDAQ: NBRV) has increased by over 15% pre-market. This is why it happened.
Nabriva Therapeutics PLC (NBRV) CEO Theodore Schroeder on Q4 2020 Results - Earnings Call Transcript
10:25pm, Thursday, 11'th Mar 2021
Nabriva Therapeutics PLC (NBRV) CEO Theodore Schroeder on Q4 2020 Results - Earnings Call Transcript
Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates
04:07pm, Thursday, 11'th Mar 2021
-Relaunched XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community with 60 sales representatives-
Nabriva Therapeutics (NBRV) Is in Oversold Territory: What's Next?
08:21am, Tuesday, 09'th Mar 2021
Nabriva Therapeutics (NBRV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021
04:05pm, Wednesday, 03'rd Mar 2021
DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a
Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
08:00am, Monday, 01'st Mar 2021
DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of i
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
04:30pm, Monday, 01'st Feb 2021
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences in January
04:01pm, Tuesday, 05'th Jan 2021
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering
11:18pm, Thursday, 10'th Dec 2020
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
Nabriva Therapeutics Announces Proposed Public Offering
04:01pm, Thursday, 10'th Dec 2020
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn
- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support
Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript
12:53am, Monday, 09'th Nov 2020
Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript
